Sign in
SuspendedPhase 1/2

A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer

Key facts

Who runs it
Shanghai Minimally Invasive Surgery Center
Where
China1 site in 1 countryChoose a country to see its locations
Trial code
Status
Suspended
Phase
Phase 1/2
People taking part
100 people, planned
Started
1 Jul 2022
Expected to end
1 Jan 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • camrelizumab+chemotherapy
  • Chemotherapy
Record updated
7 March 2024
Why it stopped
difficult in enrolling participants

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (22)Hide the full registry criteria

Who can take part

  • Subjects voluntarily join the study and sign an informed consent form, have good compliance and cooperate with follow-up
  • Male or female patients between the ages of 18-75
  • Patients diagnosed as gastric adenocarcinoma by histology or cytology
  • Stage: Locally advanced stage (T3-4aN1-3M0)
  • Have not received other immunotherapy drugs or chemotherapy drugs in the past
  • ECOG (Eastern US Cooperative Oncology Group) score: 0-1 points
  • Has sufficient organ and bone marrow function

Who cannot take part

  • Those who have multiple factors that affect oral medications (such as inability to swallow, chronic diarrhea, etc.)
  • Received glucocorticosteroid or immunosuppressive therapy within 7 days before grouping
  • Regardless of the severity, patients with any signs of bleeding or medical history; within 4 weeks before grouping, patients with any bleeding or bleeding events NCI-CTC AE V5.0 grade ≥ 3, unhealed wounds, ulcers Or fracture
  • Participated in other anti-tumor drug clinical trials within four weeks
  • According to the judgment of the investigator, those with concomitant diseases that seriously endanger the safety of the patient or affect the completion of the study
  • Other malignant tumors that have appeared or are currently suffering from within 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) ) And T1 (tumor infiltration basement membrane)]
  • Accompanied by pleural effusion or ascites, causing respiratory syndrome (NCI-CTC AE V5.0 grade ≥ 2 dyspnea)
  • Patients with any severe and/or uncontrollable disease;
  • Patients with gastrointestinal diseases with bleeding tendency (such as active gastrointestinal ulcers) or patients determined by the researcher to cause gastrointestinal bleeding, perforation or obstruction
  • Patients whose imaging shows that the tumor has invaded the tissues around important blood vessels or the investigator judges that the tumor is likely to invade important blood vessels and cause fatal bleeding during the follow-up study
  • Those who have had arterial/venous thrombotic events within 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis and pulmonary embolism
  • People with a history of psychotropic drug abuse and unable to quit or have mental disorders
  • Known hypersensitivity to any study drug
  • A distant metastasis occurs
  • Female patients who are pregnant or breastfeeding

Where is this trial?

It has locations in one country. Choose a country to see its locations.

What happens in this trial

What the trial wants to find out

It is a single-center, open-lable, randomized controlled trial to prospectively investigate the effectiveness and safety of Camrelizumab combined with DOS regimen chemotherapy in neoadjuvant treatment of patients with locally advanced gastric cancer.

The 2 groups in the trial

  • camrelizumab+chemotherapyTreatment being tested

    neoadjuvant treatment with camrelizumab+chemotherapy

  • chemotherapyExisting treatment, for comparison

    neoadjuvant treatment with chemotherapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer: a Single-center, Open-label, Randomized Controlled Trial
Record updated
7 March 2024